Law Firm Investigates NextCure Merger with Avere Therapeutics
The M&A Class Action Firm announces an investigation into the proposed merger between NextCure, Inc. (NASDAQ: NXTC) and Avere Therapeutics, Inc. The inquiry questions the fairness of the deal for NextCure shareholders.
New York – July 14, 2026 – The M&A Class Action Firm, Monteverde & Associates PC, has initiated an investigation into NextCure, Inc. (NASDAQ: NXTC) concerning its planned merger with Avere Therapeutics, Inc.
The firm is examining the terms of the transaction to determine if the proposed deal is fair to NextCure shareholders. Following the completion of the merger, NextCure shareholders are expected to collectively own approximately 1.21% of the new entity. Monteverde & Associates PC, based in New York, has a track record of recovering significant sums for shareholders in class action lawsuits.
Monteverde & Associates PC operates from the Empire State Building and specializes in securities class action litigation. The firm's lead attorney, Juan Monteverde, has been recognized in the ISS Securities Class Action Services Report.
The law firm is seeking information from NextCure shareholders who may have concerns about the merger or possess relevant details. Investors are advised to inquire about a firm's experience in class action litigation and its history of recovering funds.
Monteverde & Associates PC positions itself as a national securities class action firm with extensive experience in trial and appellate courts, including the U.S. Supreme Court.